Gilead Sciences (GILD) isn’t a one-trick pony. While the news coverage has largely fixated on its potential COVID-19 treatment, remdesivir, the large-cap has an increasingly diverse pipeline.In addition to the headline grabbing remdesivir, Gilead is the biggest player in the HIV space, manufacturing what could become the best-selling HIV drug ever, Biktarvy.Having said that, Gilead has been expanding, and through a series of M&As, building an increasingly strong oncology portfolio. Following the addition of Kite in 2018 and the more recent acquisition of cancer-focused biotech Forty Seven, Gilead has just inked a deal with immuno-oncology player Arcus Biosciences. They have agreed to a 10-year partnership to develop next-generation cancer immunotherapies. Arcus will bring a number of immuno-oncology assets to the table, including a PD-1, anti-TIGIT, CD73 inhibitor, and a dual A2a/A2b antagonist, and in return, will receive $175 million upfront, a $200 million equity investment and R&D funding to the tune...
Posted by OFX AUD - Australian Dollar The Australian dollar made fresh multi-month highs on Thursday, extending gains despite a shift in equity markets. While global equity markets faltered Thursday as investors paused to take stock of recent gains, currencies enjoyed increasing demand for risk, driving commodity and growth sensitive units higher. … Continue reading "Australian dollar makes fresh multi-month highs as risk-on narrative continues"The post Australian dollar makes fresh multi-month highs as risk-on narrative continues appeared first on ....
There’s no doubt about it, Moderna’s (MRNA) profile has increased dramatically since the pandemic’s onset.The biotech name has climbed 206% higher this year, as investors have piled in with the hope that its COVID-19 vaccine candidate, mRNA-1273, might be the one to solve the coronavirus conundrum. Yet, it hasn’t all been positive news. Recently, questions have surfaced concerning the company’s sale of shares following the stock’s latest surge.Blocking out all of the noise, Oppenheimer analyst Hartag Singh recently attended Moderna’s virtual Science Day to get some visibility on the work going on behind the scenes. The 5-star analyst liked what he heard, to say the least.“Building on the last two Science Days, Moderna has kept a focus on strengthening its Research Platform science, with (1) increasing mRNA and encoded protein half-lives and stabilizing mRNA while avoiding double-stranded RNA impurities, (2) making a novel squaramide-based ionizable lipid (new LNP) to improve protein...
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]...
In this article you are going to find out whether hedge funds think Curis, Inc. (NASDAQ:CRIS) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks among […]...
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]...
